Kevin Quon
Insider ownership, small-cap, long-term horizon, dividend investing

Intermolecular: One Step Back And Two Steps Forward

On Thursday, research acceleration specialist Intermolecular, Inc (IMI) reported its Q2 2013 earnings results. The company reported total revenues of $16.6 million, with $12.8 million derived from ongoing collaborative development programs (CDP) and $3.8 million derived from licensing and royalty revenue. Intermolecular also reported a net loss of $744,000 or $0.02/share on a GAAP basis. These statistics combined, the company was roughly in line with analyst estimates which set the expectation for $16.54 million in revenues and a loss of $0.01/share.

Intermolecular now trades with a market capitalization of $290 million according to the intraday price of $6.50 as of July 26, 2013. As of June 30, the company carried a cash balance of roughly $80 million and...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details